Pediatric Nephrology

, Volume 24, Issue 5, pp 1061–1064

Early erythropoietin reduced the need for red blood cell transfusion in childhood hemolytic uremic syndrome—a randomized prospective pilot trial

  • Lars Pape
  • Thurid Ahlenstiel
  • Martin Kreuzer
  • Jens Drube
  • Kerstin Froede
  • Doris Franke
  • Jochen H. H. Ehrich
  • Marion Haubitz
Brief Report


Childhood hemolytic uremic syndrome (HUS) is most often caused by enterohemorrhagic Escherichia coli (EHEC). Due to severe hemolysis, red blood cell (RBC) transfusions are often necessary, and anemia is aggravated by low erythropoietin (EPO) levels caused by acute renal failure. In a single center, prospective study, we randomized ten children with EHEC-positive HUS into two therapeutic groups: one receiving EPO treatment (median age 2 years, age range 1–3 years) and the other receiving standard therapy (median age 2 years, age range 1–6 years). Red blood cell transfusions were performed when the hemoglobin level (Hb) fell below 5 mg/dl. The number of RBC transfusions was compared in both groups. The Hb level at admission was comparable between both groups (6.4 vs. 8.1 mg/dl, P > 0.05, t-test). However, children in the EPO group required a significantly lower mean number of RBCs than those in the non-EPO group (0.2 vs. 1.4, P < 0.04, t-test). Based on these results, we suggest that the early administration of EPO at the time of hemolytic anemia and beginning renal failure may attenuate renal anemia in children with EHEC-induced HUS and thereby reduce the number of RBC transfusions required. The results of this pilot study will have to be confirmed in a larger multicenter trial.


Erythropoietin Free endothelial cells Hemolytic uremic syndrome 


  1. 1.
    Karmali MA (2004) Infection by Shiga toxin-producing Escherichia coli: an overview. Mol Biotechnol 26:117–122PubMedCrossRefGoogle Scholar
  2. 2.
    Tarr PI, Gordon CA, Chandler WL (2005) Shiga-toxin-producing Escherischia coli and the haemolytic uremic syndrome. Lancet 365:1073–1086PubMedGoogle Scholar
  3. 3.
    Capriolo A, Morabito S, Brugereb H, Oswald E (2005) Enterohaemorrhagic Escherischia coli: emerging issues on virulence and modes of transmission. Vet Res 36L:289–311CrossRefGoogle Scholar
  4. 4.
    Lingwood CA (2003) Shiga toxin receptor glycolipid binding: pathology and utility. Methods Mol Med 73:165–186PubMedGoogle Scholar
  5. 5.
    Boyd F, Lingwood C (1989) Verotoxin receptor glycolipid in human renal tissue. Nephron 51:207–210PubMedCrossRefGoogle Scholar
  6. 6.
    Inward CD, Howie AJ, Fitzpatrick MM, Rafaat F, Milford DV, Taylor CM (1997) Renal histopathology in fatal cases of diarrhea associated haemolytic uremic syndrome. Pediatr Nephrol 11:556–559PubMedCrossRefGoogle Scholar
  7. 7.
    Gringani G, Maiolo A (2000) Cytokines and hemostasis. Haematologica 85:967–972Google Scholar
  8. 8.
    Brandt JR, Fouser LS, Watkins SL, Zelikovic I, Tarr PI, Nazar-Stewart V, Avner ED (1994) Escherichia coli O157:h7-associated haemolytic-uremic syndrome after ingestion of contaminated hamburgers. J Pediatr 125:519–526PubMedCrossRefGoogle Scholar
  9. 9.
    Exeni R, Donato H, Rendo P, Antonuccio M, Rapetti MC, Grimoldi I, Exeni A, de Galvagni A, Trepacka E, Amore A (1998) Low levels of serum erythropoietin in children with endemic haemolytic uremic syndrome. Pediatr Nephrol 12:226–230PubMedCrossRefGoogle Scholar
  10. 10.
    Smith CH, Schulman Y, Ando R, Stern G (1955) The suppression of hematopoesis by transfusions. Blood 10:707–711PubMedGoogle Scholar
  11. 11.
    Woywodt A, Blann AD, Kirsch T, Erdbruegger U, Banzet N, Haubitz M, Dignat-George F (2006) Isolation and enumeration of circulating endothelial cells by immunomagnetic isolation: proposal of a definition and a consensus protocol. J Thromb Hemost 4:671–677CrossRefGoogle Scholar
  12. 12.
    Warady Ba, Ho M (2003) Morbidity and mortality in children with anemia at initiation of dialysis. Pediatr Nephrol 18:1055–1062PubMedCrossRefGoogle Scholar
  13. 13.
    National Collaborating Centre for Chronic Conditions (2006) Anaemia management in chronic kidney disease. National clinical guideline for management in adults and children. Royal College of Physicians, LondonGoogle Scholar
  14. 14.
    Bagnis C, Beaufils H, Jacquiaud X, Adabra Y, Jouanneau C, Le Nahour G, Jaudron MC, Bourbouze R, Jacobs C, Deray G (2001) Erythropoietin enhances recovery after cisplatin-induced acute renal failure in the rat. Nephrol Dial Transplant 16:932–936PubMedCrossRefGoogle Scholar
  15. 15.
    Iijima K, Kamioka I, Nozu K (2008) Management of diarrhea-associated hemolyic uremic syndrome in children. Clin Exp Nephrol 12:16–19PubMedCrossRefGoogle Scholar
  16. 16.
    Bell PB, Griffin M, Lozano P, Christie DL, Kobayashi JM, Tarr PI (1997) Predictors of haemolytic uremic syndrome in children during an outbreak of Escherichia coli O157:H7 infections. Pediatrics 100:E12PubMedCrossRefGoogle Scholar
  17. 17.
    Ohlsson A, Aher SM (2006) Early erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. Cochrane Database Syst Rev 3:CD004863PubMedGoogle Scholar
  18. 18.
    Fliser D, Bahlman FH, Haller H (2006) EPO: renoprotection beyond anemia correction. Pediatr Nephrol 21:1785–1789PubMedCrossRefGoogle Scholar
  19. 19.
    Westenfelder C, Biddle DL, Baranowski RL (1999) Human, rat, and mouse kidney cells excess functional erythropoietin receptors. Kidney Int 55:808–820PubMedCrossRefGoogle Scholar
  20. 20.
    Sharples EJ, Patel N, Brown P, Stewart K, Mota-Philipe H, Sheaff M, Kieswich J, Allan D, Harwood S, Raftery M, Thiemerman C, Yaqoob MM (2004) Erythropoietin protects the kidney against the injury ad dysfunction caused by ischemia-reperfusion. J Am Soc Nephrol 15:2115–2124PubMedCrossRefGoogle Scholar
  21. 21.
    Johnson DW, Pat B, Vesey DA, Guan Z, Endre Z, Gobe GC (2006) Delayed administration of darbepoetin or erythropoietin protects against ischemia acute renal injury and failure. Kidney Int 69:1806–1813PubMedCrossRefGoogle Scholar
  22. 22.
    Woywodt A, Streiber F, de Groot K, Regelsberger H, Haller H, Haubitz M (2003) Circulating endothelial cells as markers for ANCA-associated small-vessel vasculitis. Lancet 361:206–210PubMedCrossRefGoogle Scholar
  23. 23.
    Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D, CHOIR Investigators (2006) Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355:2085–2098PubMedCrossRefGoogle Scholar
  24. 24.
    Drueke TB, Locatelli F, Clyne N, Drueke TB, Locatelli F, Clyne N, Eckhardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A, CREATE Investigators (2006) Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355:2071–2084PubMedCrossRefGoogle Scholar

Copyright information

© IPNA 2008

Authors and Affiliations

  • Lars Pape
    • 1
  • Thurid Ahlenstiel
    • 1
  • Martin Kreuzer
    • 1
  • Jens Drube
    • 1
  • Kerstin Froede
    • 1
  • Doris Franke
    • 1
  • Jochen H. H. Ehrich
    • 1
  • Marion Haubitz
    • 2
  1. 1.Department of Pediatric Nephrology, Hepatology and Metabolic DiseasesMedical School of HannoverHannoverGermany
  2. 2.Department of Nephrology and Hypertensive DiseasesMedical School of HannoverHannoverGermany

Personalised recommendations